Banka BioLoo Limited has informed the Exchange regarding Outcome of Board Meeting held on May 26, 2026.
BANKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Banka BioLoo Limited reported FY26 standalone revenue of Rs. 5,975.76 lakhs (up 8.6% from Rs. 5,500.03 lakhs), with PAT turning positive at Rs. 38.21 lakhs from a loss of Rs. 929.64 lakhs in FY25. Consolidated revenue was Rs. 5,709.24 lakhs with PAT of Rs. 39.31 lakhs versus a loss of Rs. 890.87 lakhs in the prior year. Auditors issued unmodified opinions but drew emphasis of matter on Rs. 687.44 lakhs (25% of trade receivables) receivable from government bodies, with Rs. 125.26 lakhs outstanding over 2 years. A material uncertainty exists regarding Enzotech Solutions subsidiary filing for insolvency under IBC. The Board appointed Ms. Srilakshmi Manjula Chaitanya Chunduru as Company Secretary and SMAB & Associates as Internal Auditors for FY27.
The company returned to profitability after two years of losses, a positive signal. However, large outstanding government receivables and an ongoing subsidiary insolvency present collection and valuation risks. The substantial increase in consolidated borrowings (from Rs. 3.4 crore to Rs. 3.9 crore) warrants monitoring.